MYRIAD GENETICS INC

MYGN is the Nasdaq ticker symbol for Myriad Genetics, Inc., a molecular diagnostics company. The stock represents an ownership stake in a business focused on genetic testing and precision medicine. Its price reflects investor expectations about the company's testing products, reimbursement environment, and overall growth prospects in the diagnostics sector.

MYGN operates in the healthcare sector, specifically within molecular diagnostics and life sciences. The company develops and markets genetic tests used in areas such as oncology, women's health, and mental health. Demand for these services is tied to clinical adoption, insurance coverage decisions, and medical research trends that shape the broader diagnostics industry.

Recent performance for MYGN depends on daily market activity and company-specific news. The page displays the latest price, percentage change, and historical trends. Investors can check the performance chart and recent trading data on this page to see how MYGN has moved over various timeframes rather than relying on outdated figures.

Valuation analysis for MYGN often involves comparing its price to financial fundamentals. Because diagnostics companies can have uneven earnings, investors may review price-to-sales, price-to-book, and forward estimates alongside cash flow. It is also useful to compare these metrics with peers in the life sciences and molecular diagnostics space. The page's valuation data provides current figures for that assessment.

You can buy MYGN through a licensed brokerage account by placing a market or limit order during regular trading hours. Most online brokers allow U.S. stocks like MYGN to be purchased in whole shares, and some may support fractional shares. Before trading, confirm commissions, order types, and any account minimums required by your broker.

Key risks for MYGN include reimbursement pressure from insurers and government payers, competition in genetic testing, and the need to keep pace with rapid scientific and technological change. Regulatory shifts, clinical trial outcomes, and reliance on key products or partnerships can also affect results. These factors can influence revenue, margins, and the stock's market value.